Aripiprazole Injection and Posaconazole: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Posaconazole
Aripiprazole Injection
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased ARIPiprazole exposure and an increased risk of QT interval prolongation
Interaction Deep Dive
Use of posaconazole and ARIPiprazole is contraindicated, as it may increase ARIPiprazole exposure and risk of QT interval prolongation5. Reduce ARIPiprazole dose by 50% if taking with posaconazole and by 25% if taking with dual CYP3A/CYP2D6 inhibitors 2. If posaconazole use exceeds 14 days, reduce ARIPiprazole IM dose 400 mg to 300 mg, or 300 mg to 200 mg 3. Avoid ARIPiprazole extended release 2-months in patients on strong dual CYP3A/CYP2D6 inhibitors. If posaconazole use exceeds 14 days, use 720 mg once every 2 months. Similarly, if coadministered for less than 14 days, then no dosage adjustment of ARIPiprazole is needed. Increase the ARIPiprazole dose once posaconazole is discontinued 1. If coadministered, reduce Aristada(R) to the next lower strength, no dose change for 441 mg monthly is needed if tolerated 4.
Why it happens (mechanism)
Inhibition of CYP3A-mediated metabolism of ARIPiprazole; additive QT interval prolongation
Literature reports
1 report — tap to read
Common questions
Can I take Aripiprazole Injection and Posaconazole together?
Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Always confirm with your pharmacist or prescriber before making any change.
How serious is the Aripiprazole Injection and Posaconazole interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Aripiprazole Injection or Posaconazole need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (5)
- Product Information: ABILIFY ASIMTUFII(R) intramuscular extended-release suspension, aripiprazole intramuscular extended-release suspension. Otsuka America Pharmaceutical Inc (per FDA), Rockville, MD, 2023.
- Product Information: ABILIFY(R) oral tablets, oral solution, intramuscular injection, aripiprazole oral tablets, oral solution, intramuscular injection. Otsuka America Pharmaceutical Inc (per FDA), Rockville, MD, 2022. DailyMed
- Product Information: ABILIFY MAINTENA(R) intramuscular extended-release injection, aripiprazole intramuscular extended-release injection. Otsuka America Pharmaceutical Inc (per FDA), Rockville, MD, 2020.
- Product Information: ARISTADA(R) intramuscular extended-release injection, aripiprazole lauroxil intramuscular extended-release injection. Alkermes Inc (per FDA), Waltham, MA, 2018.
- Product Information: NOXAFIL(R) intravenous injection, oral delayed-release tablets, oral suspension, posaconazole intravenous injection, oral delayed-release tablets, oral suspension. Merck Sharp & Dohme LLC (per FDA), Rahway, NJ, 2024. DailyMed
Keep reading about Posaconazole
Keep reading about Aripiprazole Injection
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist